Pharmacological compliance and acceptability of lansoprazole orally disintegrating tablets in primary care

References

• Catálogo de especialidades farmacéuticas. Ed. Consejo General de Colegios Oficiales de Farmacéuticos, 2000
   Google Scholar
• Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion 2003;67:1–5
   PubMed Web of Science ®Google Scholar
• Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study [NSAID-Associated Gastric Ulcer Study Group]. Arch Intern Med 2000;160:1455–61
   PubMed Web of Science ®Google Scholar
• Andersen O, Zweidorff OK, Hjelde T, Rodland E.A. Problems when swallowing tablets. A questionnaire study from general practice (in Norwegian). Tidsskr Nor Laegeforen 1995;115:947–9
   PubMedGoogle Scholar
• D’Eliseo P, Blaauw J, Milicevic Z, et al. Patient acceptability of a new 3.0 mL pre-filled insulin pen. Curr Med Res Opin 2000;16: 125–33
   Google Scholar
• Lake Y, Pinnock S. Improved patient acceptability with a transdermal drug-in-adhesive oestradiol patch. Aust New Zealand J Obstet Gynaecol 2000;40:313–6
   PubMed Web of Science ®Google Scholar
• Rees TP, Howe I. A randomized, single-blind, crossover comparison of the acceptability of the calcium and vitamin D3 supplements Calcichew D3 Forte and Ad Cal D3 in elderly patients. Curr Med Res Opin 2001;16:245–51
   PubMed Web of Science ®Google Scholar
• Ristic S, Bates PC, Martin JM, Llewelyn JA. Acceptability of a reusable insulin pen, HumaPen Ergo, by patients with type 1 and type 2 diabetes. Curr Med Res Opin 2002;18:68–71
   PubMed Web of Science ®Google Scholar
• Barnebey H, Kwok SY. Patients’ acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000;22:1204–12
   PubMed Web of Science ®Google Scholar
• Stanhope R, Buchanan C, Butler G, et al. An open-label acceptability study of Norditropin SimpleXx – a new liquid growth hormone formulation. J Pediatr Endocrinol Metab 2001;14:735–40
   PubMed Web of Science ®Google Scholar
• Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001;24:1556–9
   PubMed Web of Science ®Google Scholar
• Kaplan MR, Stashenko CL, Bledsoe AL, McGowan J. A preference study: calcium acetate tablets versus gelcaps in hemodialysis patients. Nephrol Nurs J 2002;29:363–5
   PubMedGoogle Scholar
• Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24:1871–86
   PubMed Web of Science ®Google Scholar
• Cotterell EM, Gazarian M, Henry RL, et al. Child and parent satisfaction with the use of spacer devices in acute asthma. J Paediatr Child Health 2002;38:604–7
   PubMed Web of Science ®Google Scholar
• Bailey ME, Garrett WV, Nisar A, et al. Day-case laparoscopic Nissen fundoplication. Br J Surg 2003;90:560–2
   PubMed Web of Science ®Google Scholar
• Saruc M, Sertdemir A, Turkel N, et al. Midazolam-induced sedation for upper gastrointestinal endoscopy: assessment of endoscopist and patient satisfaction. Gastroenterol Nurs 2003;26:164–7
   PubMedGoogle Scholar
• McIntosh IB. Butazolidin suppository medication in rheumatism; a clinical study in general practice. J Int Med Res 1977;5:81–4
   PubMed Web of Science ®Google Scholar
• Andren-Sandberg A. Theory and practice in the individualization of oral pancreatic enzyme administration for chronic pancreatitis. Int J Pancreatol 1989;5:51–62
   PubMedGoogle Scholar
• Hungin APS, Rubin GP, O´Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999;49:463–4
   Google Scholar
• Pilotto A, Franceschi M, Leandro G, et al. Comparison of four pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J Gastroenterol 2007;13:4467–72
   PubMed Web of Science ®Google Scholar
• Chiba N, Marshall CP. Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori. Can J Gastroenterol 2000;14:27–31
   PubMed Web of Science ®Google Scholar
• Miwa H, Yamada T, Sato K, et al. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. Dig Dis Sci 2000;45:77–82
   PubMed Web of Science ®Google Scholar
• Wong BC, Wong WM, Yee YK, et al. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2001;15: 1959–65
   PubMed Web of Science ®Google Scholar
• Hall J, Dodd S, Durkin M, Sloan S. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. Manag Care 2002;11:14–8
   PubMedGoogle Scholar
• Wong WM, Lai KC, Hui WM, et al. Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004;19:455–62
   PubMed Web of Science ®Google Scholar
• Hsu PI, Lai KH, Lin CK, et al. A prospective randomized trial of esomeprazole-versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005;100:2387–92
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Domínguez-Muñoz A, Domínguez-Martín A, et al. Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? Am J Gastroenterol 2005;100: 1935–40
   Google Scholar
• Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. J Clin Pract 2005;59:1210–7
   Google Scholar
• Freston JW, Chiu YL, Mulford DJ, Ballard ED. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003;17:361–7
   PubMed Web of Science ®Google Scholar
• Hintze J. NCSS and PASS. Kaysville (UT): Number Cruncher Statistical Systems; 2001
   Google Scholar
• Sackett DL, Snow JC. The magnitude of compliance and noncompliance. Compliance in Health Care. Baltimore: Johns Hopkins; 1979
   Google Scholar
• Hungin APS, Rubin GP, O´Flanagan H. Long-term prescribing of proton pump inhibitor therapy in general practice. Br J Gen Pract 1999;49:451–3
   Google Scholar